ATG-008 (also known as CC-223) is an oral, second-generation mammalian target of rapamycin (mTOR) kinase inhibitor, which blocks both mTOR complex 1 (TORC1) and mTOR complex 2 (TORC2). It has demonstrated to induce tumor cell apoptosis and decrease tumor cell proliferation. We are in partnership with Celgene to develop, manufacture and commercialize this compound in 14 countries/regions in Asia.
mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is dysregulated in approximately eighty percent of human cancers. mTOR links with other proteins and serves as a core component of two distinct protein complexes, TORC1 and TORC2, which regulate different cellular processes. Currently, two first-generation mTOR inhibitors (everolimus and temsirolimus), targeting solely TORC1, are marketed globally for multiple oncology indications.
2017 Albert Lasker Basic Medical Research Award was granted to Michael N. Hall, who discovered the nutrient-activated TOR proteins and their central role in the metabolic control of cell growth.
ATG-008 is currently conducting registrational Phase 2/3 clinical studies for treatment of solid tumors in Asian countries and regions.